ORGO
Organogenesis Holdings Inc.
ORGO lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
ORGO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Strong |
ORGO's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
ORGO PE Valuation
ORGO has no meaningful PE right now: it lost money over the past year.
ORGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect ORGO's losses to shrink, with revenue declining.
ORGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.15 | -$1.04 |
| Q2 2026 | -$0.79 | -$0.66 |
| Q1 2026 | -$0.12 | +$0.04 |
| Q4 2025 | $0.15 | +$0.16 |
| Q3 2025 | -$0.11 | -$0.05 |
| Q2 2025 | -$0.13 | $0.00 |
| Q1 2025 | -$0.16 | -500% |
| Q4 2024 | -$0.01 | -125% |
ORGO lost $1.15 per share over the past year, and its loss has widened in each of the last three quarters.
ORGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $45.5M | -70% |
| Q2 2026 | $43.8M | -57% |
| Q1 2026 | $37.2M | -57% |
| Q4 2025 | $225.6M | +78% |
| Q3 2025 | $150.9M | +31% |
| Q2 2025 | $101M | -22% |
| Q1 2025 | $86.7M | -21% |
| Q4 2024 | $126.7M | +27% |
ORGO's revenue is shrinking: $45M last quarter, down 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -65% | -79 points |
| Q2 2026 | -117% | -104 points |
| Q1 2026 | -185% | -154 points |
| Q4 2025 | 28% | +20 points |
| Q3 2025 | 14% | +8.3 points |
| Q2 2025 | -12% | -1.8 points |
| Q1 2025 | -31% | -27 points |
| Q4 2024 | 8.1% | +9.3 points |
ORGO's operating margin was −65% last quarter, down 79 points from the same quarter a year ago, near the bottom of its range since 2019.
ORGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.1M | -2477% |
| Q2 2026 | -$32.8M | +$3.8M |
| Q1 2026 | $18M | +$41.5M |
| Q4 2025 | $34.8M | +359% |
| Q3 2025 | $844K | -86% |
| Q2 2025 | -$36.5M | -1378% |
| Q1 2025 | -$23.6M | -$11.2M |
| Q4 2024 | $7.6M | +3.9% |
ORGO's free cash flow was −$64,000 over the past year, against −$52M the year before.
ORGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +316K shares |
| 1 year | -1.4% | -1.9M shares |
| 3 years | -3.3% | -4.4M shares |
| 5 years | -3.6% | -4.9M shares |
| Available history | +39% | +36.2M shares |
ORGO has 129M diluted shares, down 1.4% from a year ago.
ORGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -4.9x | Net Cash |
| Q4 2025 | -1.6x | Net Cash |
| Q3 2025 | -9.9x | Net Cash |
| Q4 2024 | -10.2x | Net Cash |
| Q3 2024 | -13.6x | Net Cash |
| Q2 2024 | -6.0x | Net Cash |
| Q1 2024 | -0.8x | Net Cash |
| Q4 2023 | -1.3x | Net Cash |
ORGO has more cash than debt.
ORGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.3 | Oversold |
| Stochastic | 7.8 | Oversold |
ORGO's weekly RSI is 27 (oversold) and its Stochastic is 8 (oversold).
ORGO PE vs Healthcare Sector
| Metric | ORGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ORGO has no meaningful PE right now: it lost money over the past year.
ORGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.07 | 10% below |
| 20 week MA | $1.63 | 41% below |
| 50 week MA | $2.60 | 63% below |
| 100 week MA | $3.40 | 72% below |
| 200 week MA | $3.18 | 70% below |
ORGO is in a downtrend: it's below all five of its weekly moving averages, and 70% below its 200-week average.
ORGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.94 | $6.46 | +31% |
| 2021 | $6.46 | $10.2 | +58% |
| 2022 | $10.2 | $2.59 | -75% |
| 2023 | $2.59 | $4.09 | +58% |
| 2024 | $4.09 | $3.19 | -22% |
| 2025 | $3.19 | $5.28 | +66% |
| 2026 YTD | $5.28 | $0.96 | -82% |
ORGO is down 82% so far in 2026, after finishing higher in four of the previous six years.